Cohort profile: A multicenter evaluation of clinical decision rules applied to emergency department triage of patients presenting with acute respiratory infection or infectious diarrhea

Purpose Emergency department (ED) patients suffering from acute respiratory infection or infectious diarrhea often present with self-limiting conditions. The study objective was to evaluate the performance of triage clinical decision rules consisting of a rapid molecular test and a self-administered patient questionnaire to identify ED patients who can self-treat at home without consulting an emergency physician. This article describes the profile of the cohorts recruited. Participants Participants were prospectively recruited in 4 EDs in Québec City and Montréal, Canada, from February 2022 through March 2023. Participants were aged ≥18 years, had an acute respiratory infection and/or acute infectious diarrhea, and had received a Canadian Triage and Acuity Scale score between 3 (urgent) and 5 (non-urgent). Participants were asked to complete a self-administered risk stratification questionnaire after triage and to follow usual ED care afterward. Nasopharyngeal and/or rectal swabs were collected and frozen for subsequent testing on a rapid molecular testing device. Data were obtained during the recruitment visit, during a follow-up phone call 7 days later and from medical records. The primary outcome to be predicted by the clinical decision rules was an aggregation of hospitalization, return visit and mortality at 7 days. Findings to date We recruited 1,391 participants, 62.3% of whom were women, 80.7% were aged under 60, 78.2% had no comorbidities, 76.5% presented with an acute respiratory infection, 17.8% with an acute infectious diarrhea and 5.7% with both. Hospitalization and return visits incidence proportions at 7 days were respectively 10.8% and 13.1% for respiratory infections and 14.1% and 16.5% for infectious diarrhea. No death was recorded. Future plans The data gathered from these cohorts will enable us to test, refine, derive, and validate clinical decision rules used to help ED triage nurses offer the most suitable care to patients presenting with acute respiratory infections or infectious diarrhea. Strengths and limitations Our study has both strengths and limitations. Among the strengths: 1. The cohorts were recruited from 4 different EDs and reached the target sample size for acute respiratory infections and acute infectious diarrhea. 2. The potential economic impact of the clinical decision rules will be assessed from the perspective of both the health system and the patient. The main limitations are the following. 1. Cohorts were recruited by convenience sampling and may not be representative of the entire ED population. 2. The patient self-administered questionnaires used in this study were derived from systematic reviews and rapid prototyping, but not according to the methodological standards recommended for the derivation of clinical decision rules. However, the study dataset was built to enable rules to be refined and if necessary, new rules to be derived and internally validated. 3. We recorded a 12.9% loss of participants at the 7-day follow-up phone call. However, the primary outcome measures (return visits, admissions and deaths) will be obtained from provincial administrative databases. These reliable data will enable us to overcome this limitation for future projects to refine and validate robust triage clinical decision rules. ### Competing Interest Statement The research team received funding from Meridian Bioscience to develop PCR assays. The BioFire assays used in this study were duly purchased from Biomerieux. However, none of these companies had influence over study design or on any of the data published in this manuscript. ### Clinical Trial NCT05322694 ### Funding Statement This study was funded by the Ministere de l'economie et de l'innovation du Quebec ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: Ethics committee/IRB of Centre de recherche du CHU de Quebec-Universite Laval gave ethical approval for this work I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes The data sets generated during and/or analyzed during this study are available from the corresponding author on reasonable request.